Alexion Pharmaceuticals (ALXN) Ready to Breakout?

An ascending triangle pattern has emerged in the chart of Alexion Pharmaceuticals (ALXN) and a breakout is expected soon…

Alexion Pharmaceuticals (ALXN) specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for a variety of disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.

The company reported its latest financial results last month and beat estimates on both revenue and earnings. Revenue was driven by strong momentum in Soliris and its recent label expansions. Its next generation drug, Ultomiris, is also selling very well and is being evaluated for COVID-19 treatment.

ALXN had $2.3 billion in cash at the end of the third quarter. This was down from $2.9 billion in the previous quarter and below its long-term debt of $2.6 billion. Though the company has a healthy current ratio of 3.8.

The firm has a strong history of revenue growth with a five-year growth average of 18.5%. Sales are expected to grow 9.7% next year. The stock’s Price to Earnings ratio is 27.8, well below the S&P 500. Its Price to Book ratio is also relatively low at 2.4.

The stock has shown mixed momentum as it has been trending downward over the last month, but has shown stronger long-term momentum. ALXP is rated a “Buy” by our POWR Ratings system.

Take a look at the 1-year chart of ALXN below with the added notations…

See chart and continue reading at